Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001976442 | SCV002264272 | uncertain significance | Developmental and epileptic encephalopathy, 12 | 2021-12-24 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. This variant has not been reported in the literature in individuals affected with PLCB1-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.007%). This sequence change replaces methionine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 592 of the PLCB1 protein (p.Met592Leu). |
Ambry Genetics | RCV004042298 | SCV005006452 | uncertain significance | Inborn genetic diseases | 2023-12-12 | criteria provided, single submitter | clinical testing | The c.1774A>T (p.M592L) alteration is located in exon 18 (coding exon 18) of the PLCB1 gene. This alteration results from a A to T substitution at nucleotide position 1774, causing the methionine (M) at amino acid position 592 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |